Background: Although recent studies suggest high accuracy of breast magnetic resonance imaging (MRI) in predicting residual tumor extent after neo-adjuvant systemic treatment (NST), its use is still controversial. In this study, we aimed to identify predictive factors of MRI accuracy after NST to determine a subgroup of patients in whom the use of MRI provides best additional benefit.
introduction Neo-adjuvant systemic treatment (NST) has now become widely accepted as the standard treatment for the patients with locally advanced breast cancer (LABC) [1] . NST increases breast conservation rates without compromising oncologic outcomes [2, 3] . However, invasive breast cancers often show heterogeneous responses to NST. Some tumors shrink concentrically to form a single foci of residual tumor cells while others leave scattered tumor cells in patchy patterns [3, 4] . Furthermore, physical examination and mammography are often inaccurate in differentiating chemotherapy-induced fibrosis from residual invasive cancer [5] [6] [7] . These difficulties in delineating tumor extent after NST can be problematic since repeated excision may undermine the cosmetic benefit of breast conservation, and inadequate resection may harbor future local relapse.
Recent studies suggest breast magnetic resonance imaging (MRI) to be an accurate diagnostic tool for evaluating the extent of residual disease after NST [8, 9] . This relatively high accuracy of breast MRI has translated into the general concept that MRI seems to be clinically indicated in LABC patients who underwent NST [10] . However, despite its superior accuracy when compared with other modalities, MRI still has certain rates of over-or underestimation of residual tumor extent. This inaccurate assessment has been suggested to be influenced by tumor response, chemotherapeutic agent, or NST-induced reactive changes within the tumor [10] .
Considering this wide spectrum of MRI accuracy in determining residual tumor extent after NST, we hypothesized that certain patient subgroup with higher MRI accuracy may exist. Chen et al. [11, 12] have recently suggested that molecular characteristics of primary breast cancer may also affect the accuracy of preoperative MRI in patients who underwent NST. Therefore, we investigated molecular profiles of tumors as well as clinicopathologic parameters of patients who received NST. In this study, we show that patients' age and HER2 expression Table 1 . One hundred and seventy patients (87.2%) were treated with taxane plus anthracycline regimens and 14 patients (7.2%) with anthracycline-based regimens. The remaining 11 patients (5.6%) received trastuzumab plus taxane regimen.
MRI acquisition and image analysis
Our protocol for MRI acquisition and data analysis until January 2007 has been reported previously [13] . Briefly, MRI was carried out with a 1.5-T imager (Sonata; Siemens Medical Systems, Erlangen, Germany). Dynamic contrast-enhanced images with one precontrast and four postcontrast series were obtained, using a T1-weighted three-dimensional (3D) fast low-angle shot sequence with fat suppression in a one-sided sagittal plane (TR 4.9 ms, TE 1.8 ms, flip angle 12°, field of view 170 mm, matrix 224 · 448, time of acquisition 84 s, 1.0-mm section thickness with no gap). A bolus of gadopentetate dimeglumine (Magnevist; Schering, Berlin, Germany) was injected i.v. at a dose of 0.1 mmol/kg of body weight within 15 s, followed by a 20 ml saline solution flush.
Postprocessing subtraction of the dynamic images was carried out for all patients. We obtained two different series of subtracted images for each patient: images obtained before the administration of contrast material were subtracted from the early-phase (84 s) images obtained after the administration of contrast material, and delayed phase (336 s) images were subtracted from the early-phase postcontrast images. The first set of the subtracted images showed early enhancement of the lesions and the second set showed temporal changes in the enhancement pattern between each pair of early and delayed phase images.
After February 2007, all MRI examinations were carried out by a 1.5-T system (Signa, General Electric Medical Systems, Milwaukee, WI) using a dedicated breast coil (Liberty 5000, USA Instruments, Aurora, OH). After an axial localizer image was obtained, a sagittally oriented fat-suppressed fast spin-echo T2-weighted sequence (TR/TE, variable from 5500 to 7150/82; 256 · 160 matrix; 1.2-mm slice thickness; no gap) was carried out. Then, dynamic contrast-enhanced MRI was carried out as follows: precontrast image with a T1-weighted fat-suppressed 3D fast spoiled gradient echo sequence (TR/TE, 6.5/2.5; 320 · 160 matrix; 1.5-mm slice thickness; no gap), postcontrast images in 2 min after contrast administration, after 4 min from the initial injection, and after about 6-7 min. In addition, sagittal subtraction, axial reformats, and 3D maximum intensity projection images were generated by postprocessing process.
pathologic assessment
The pathologic complete response (pCR) was defined as complete disappearance of invasive carcinoma in primary tumor area. Residual tumor size was defined as the size of invasive cancer including the surrounding area of in situ lesion. ER, PR, and HER2 expressions were evaluated by the standard avidin-biotin complex immunohistochemical staining method as previously described [14] . All primary antibodies were mAbs: ER (Dako Corporation, Carpinteria, CA; 1:50), PR (Dako Corporation, 1 : 50), and c-erbB2 (Novocastra Laboratories Ltd, New Castle-Upon-Tyne, UK; 1 : 200). Biotinylated anti-mouse antibody was used as secondary antibody and streptavidin-horseradish peroxidase (Zymed Laboratories, San Francisco, CA) methods were used.
A cut-off value of 10% was used to define ER and PR positivity. HER2 expression was initially assessed by immunohistochemical staining, and 
results
The overall accuracy of breast MRI in predicting the residual tumor extent is shown in Figure 1A . MRI predicted the residual tumor extent more accurately than ultrasonography (USG) (r = 0.584 and r = 0.495, respectively). Pathologic complete remission (pCR) was achieved in 29 patients (14.9%), and MRI predicted pCR with a sensitivity of 37.9% and specificity of 96.4%. The accuracy of MRI was further studied in each molecular subtype of patients ( Figure 1B) . The correlation of MRI-measured tumor size and pathologic tumor size was highest in patients with TN subtype (r = 0.781) when compared with other subtypes (LumA: 0.504, LumB: 0.502, and HER2: 0.384). Interestingly, patients with HER2 subtype tumors showed markedly lower correlation between MRImeasured tumor size and pathologic tumor size ( Figure 1B) . Absolute discrepancies between MRI-measured residual tumor extent and pathologic tumor extent were compared between subgroups defined by various clinicopathologic and molecular parameters (Table 2 ). Among the various factors, univariate analysis suggested age as a single significant factor in determining MRI accuracy. Relatively older patients ( ‡45) had significantly higher accuracy of MRI (P = 0.001). 
original article Annals of Oncology
On the other hand, patients with HER2-negative tumors, nondense breast, and TN subtype tumors showed higher MRI accuracy when compared with others, but of no statistical significance.
However, multivariate analysis using linear regression analysis showed that age and HER2 expression status are both independent predictors of MRI accuracy for residual tumor extent after NST (Table 3) . Older age ( ‡45) and HER2-negative tumors were associated with increased accuracy of breast MRI. As mentioned before, HER2 FISH was not carried out in 8 of 37 patients with 2+ HER2 immunohistochemistry. However, multivariate analysis after excluding those eight patients also showed that age and HER2 expression status are independent predictors of MRI accuracy (P value of 0.006 and 0.029 for age >45 and HER2 positivity, respectively).
From the results of linear regression analysis, we classified the patients into three groups based on age and HER2 expression status. Older patients with HER2-negative tumors were classified as 'high-accuracy group' and younger patients with HER2-positive tumors as 'low-accuracy group'. Others were classified as 'intermediate-accuracy group'. As expected, this classification based on age and HER2 expression status predicted MRI accuracy in the studied patients (Figure 2A) . In low-accuracy group, MRI did not have additional diagnostic benefit in predicting residual tumor extent when compared with the preoperative USG (r = 0.392 and r = 0.425 for MRI and USG, respectively).
Subsequently, these observations were validated using an independent cohort. In a prospectively maintained validation cohort of 63 patients, the predictive role of age and HER2 expression status was maintained ( Figure 2B) . Again, younger patients with HER2-negative tumors had highest MRI accuracy in predicting residual tumor extent (r = 0.849).
discussion
Present study demonstrates the superior accuracy of breast MRI in predicting residual tumor extent following NST in general. Also, it shows that patients' age and HER2 expression status of primary tumor affect the accuracy of preoperative MRI. Relatively older patients with HER2-negative tumors showed highest MRI accuracy. There have been reports that suggest the superior accuracy of MRI when compared with other modalities in estimating residual tumor extent after NST [8, 9] , but most studies focused on the overall accuracy rather than identifying certain subgroup of patients in whom the benefit of MRI can be maximized. We show that such a subgroup exists and can be defined by easily accessible information such as patient's age and HER2 status.
Scattered pattern of tumor response after NST makes it difficult for surgeons to determine the extent of surgery, especially during breast conservation. This inadequate breast conservation may lead to repeated surgery for positive resection margin or may result in false sense of safety despite the remaining scattered cancer cells. Remaining viable cancer cells can be a potential source of ipsilateral breast tumor recurrence (IBTR). Although a recent meta-analysis suggested that NST in operable breast cancer does not hamper the local control of disease [16] , data from prospective clinical trials often give rise to the concerns of increased IBRT after NST [2, 17, 18] . IBRT after NST can partly be explained by remaining cancer cells from inadequate surgery. In fact, a multifocal or breakup pattern of residual disease has been shown to be associated with increased locoregional recurrence [19] . On the other hand, overestimating residual tumor extent is also problematic since it can lead to unnecessary mastectomies. Therefore, accurate preoperative determination of residual tumor extent after NST is critical for local tumor control. Our result, in together with other previous reports, shows that breast MRI is the most accurate method of predicting residual tumor extent after NST [8, 9] . However, in younger patients with HER2-positive tumors, the accuracy of MRI decreased significantly.
The identification of distinct subgroup of patients in whom MRI accuracy is substantially reduced carries certain clinical implications. While preoperative breast MRI can detect additional tumors which are otherwise undetected, the use of preoperative MRI has been consistently criticized for its high false-positive rate. Furthermore, the clinical significance of even those true-positive lesions is not clear [20] . As a result, routine use of breast MRI after NST is still controversial despite its high accuracy in preoperative evaluation [3, 10] . Current findings can provide more tailored approach to the use of preoperative MRI in patients undergoing NST. Although our results do not directly address the clinical benefit from using 
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MRI, it suggest that in younger patients with HER2-positive tumors, additional benefit from breast MRI may be minimal while disadvantages persist. The biologic mechanisms explaining the association of MRI accuracy with age and HER2 expression status are not clear. One possible explanation can be the differential degree of angiogenesis in breast cancer. Angiogenesis is a critical factor in determining accuracy of contrast-enhanced MRI in imaging tumor tissues [21] . HER2 overexpression is closely associated with increased angiogenesis [22] , possibly by modulating proand antiangiogenic factors [23, 24] . MRI features of breast cancer tissue are also affected by histologic grade of tumors. Dynamic enhancement patterns as well as morphologic patterns of breast MRI have been reported to be associated with tumor grade [25, 26] . Younger patients are more likely to have tumors with higher histologic grade, thereby affecting the MRI accuracy [27, 28] .
However, in this study, patients whose tumors are more likely to have higher degree of angiogenesis (young age and HER2-positive tumors) had lower accuracy of breast MRI, which may seem contradictory to the literatures. A possible explanation is that a high level of angiogenesis within the tumor at the time of diagnosis may interfere with accurate post-NST imaging of tumor using breast MRI due to residual angiogenesis. Indeed, abnormal neovascularization is shown to be persistent in resected breast specimens despite the complete original article Annals of Oncology tumor response to NST [29] . Makris et al. [30] also reported that the reduction of angiogenesis did not correlate to tumor response to NST from their analysis of 90 patients undergoing NST.
In contrary with our findings, Chen et al. [12] reported that MRI predicted pCR more accurately in patients with HER2-positive tumors in their study including 51 breast cancer patients. Different from our study, they treated all HER2-positive tumors with trastuzumab, an agent which effectively modulates angiogenic activity. In our study, only 5.6% of patients received preoperative trastuzumab treatment. This difference in the use of antiangiogenic agents may partly explain the disagreements in results. Furthermore, same investigators also reported an impressive accuracy of MRI (r = 0.998) in patients with triple-negative tumors (which are at least HER2 negative) [11] . Therefore, we believe that the effect of molecular subtypes on MRI accuracy should be further validated in future as well as the relationship between MRI accuracy and various molecular-targeted agents.
In conclusion, this study demonstrates that age and HER2 expression status affect the accuracy of MRI in predicting residual tumor extent after NST. Although MRI showed superior correlation with pathologic tumor size when compared with USG, the additional benefit of MRI seems minimal in younger patients with HER2-positive tumors. We believe that these observations may guide more judicious and tailored use of breast MRI in patients undergoing NST.
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